Are You in Florida for Spring Training? Come meet Globe Sports Writers Nick Cafardo and Peter Abraham! Click for more info.

Novartis, Amgen join venture fund

The biopharmaceutical companies Novartis AG and Amgen Inc. have signed on as limited partners in a new $265 million venture capital fund raised by the Cambridge firm Atlas Venture.

The new fund, Atlas Venture Fund IX, will invest in biomedical and life sciences start-ups.

Continue reading below

Separately, Novartis, a Swiss company that runs its global research operations from Cambridge, and California-based Amgen, which also has a research center in ­Cambridge, have entered into corporate strategic partnerships with Atlas Venture, the partners said.

The alliances will “provide Amgen and Novartis with strategic proximity to Atlas Venture’s start-up formation activities around innovative, potentially high impact medicines, and catalyze future collaborations around translational research,” the venture firm said in a statement.

Robert Weisman can be reached at weisman@globe.com. Follow him on Twitter @GlobeRobW.
Loading comments...

Wake up with today's top stories.

Want each day's news headlines delivered fresh to your
inbox every morning? Just connect with us
in one of the following ways:
or
Please enter a valid email
BostonGlobe.com will never post anything without asking. Privacy Policy
Subscriber Log In

You have reached the limit of 5 free articles in a month

Stay informed with unlimited access to Boston’s trusted news source.

  • High-quality journalism from the region’s largest newsroom
  • Convenient access across all of your devices
  • Today’s Headlines daily newsletter
  • Subscriber-only access to exclusive offers, events, contests, eBooks, and more
  • Less than 25¢ a week
Marketing image of BostonGlobe.com
Marketing image of BostonGlobe.com